Alan S. Go, MD; Carlos Iribarren, MD, MPH, PhD; Malini Chandra, MS, MBA; Phenius V. Lathon; Stephen P. Fortmann, MD; Thomas Quertermous, MD; Mark A. Hlatky, MD; for the Atherosclerotic Disease, Vascular Function and Genetic Epidemiology (ADVANCE) Study
This case–control study of 1384 adults from a large prepaid group practice evaluated the effect of current use of statins or β-blockers at first presentation of coronary heart disease. Use of these drugs was associated with lower odds of presenting with an acute myocardial infarction and higher odds of presenting with stable angina. Additional studies are needed to prove that these therapies protect against unstable, higher-risk clinical presentations of coronary disease.
Ann Intern Med. 2006;144(4):229-238. doi:10.7326/0003-4819-144-4-200602210-00004
Bronwyn A.L. Crawford, MBBS, PhD; Cherie Kam, MPH, GDipScMed; Julie Pavlovic, RN; Karen Byth, PhD, DIC, CStat RSS; David J. Handelsman, MBBS, PhD; Peter W. Angus, MBBS, MD; Geoffrey W. McCaughan, MBBS, PhD
Clinically important rapid bone loss occurs within 3 to 6 months after liver transplantation and may be associated with osteoporotic fractures. In this clinical trial, bone mineral density decreased during the postoperative period in patients taking placebo but did not change in patients taking zoledronic acid.
Ann Intern Med. 2006;144(4):239-248. doi:10.7326/0003-4819-144-4-200602210-00005
Mary J. Roman, MD; Elfi Moeller, AB; Adrienne Davis, AB; Stephen A. Paget, MD; Mary K. Crow, MD; Michael D. Lockshin, MD; Lisa Sammaritano, MD; Richard B. Devereux, MD; Joseph E. Schwartz, PhD; Daniel M. Levine, PhD; Jane E. Salmon, MD
Rheumatoid arthritis is associated with increased morbidity and mortality due to cardiovascular disease. In this matched, cross-sectional study, patients with rheumatoid arthritis had a somewhat more favorable cardiovascular risk profile than the controls. Nonetheless, patients with rheumatoid arthritis had a much higher prevalence of preclinical atherosclerosis of the carotid artery than did the matched controls.
Ann Intern Med. 2006;144(4):249-256. doi:10.7326/0003-4819-144-4-200602210-00006
Stephen Bent, MD; Amy Padula, MS; Andrew L. Avins, MD, MPH
In an existing clinical trial, 214 men were divided into 3 groups to measure the effect of 3 methods to assess adverse events: an open-ended question; an open-ended, defined question; and a checklist of 53 common side effects. The checklist group was much more likely to report an adverse event (14%, 13%, and 77%, respectively). Researchers should use the same method to assess adverse events in clinical trials.
Ann Intern Med. 2006;144(4):257-261. doi:10.7326/0003-4819-144-4-200602210-00007
Peter K. Lindenauer, MD, MSc; Raj Behal, MD, MPH; Cynthia K. Murray, PhD; Wato Nsa, MD, PhD; Peter M. Houck, MD; Dale W. Bratzler, DO, MPH
In this study of the annual pneumonia caseload of physicians and hospitals, the number of cases was not a powerful determinant of quality of care or outcome. Higher volume was associated with lower adherence to guideline recommendations. The best targets for quality improvement efforts were the timeliness of antibiotic administration, especially at high-volume institutions, and hospital-based vaccination rates.
Ann Intern Med. 2006;144(4):262-269. doi:10.7326/0003-4819-144-4-200602210-00008
Jon-Erik C. Holty, MD, MS; Dena M. Bravata, MD, MS; Hau Liu, MD, MPH, MBA; Richard A. Olshen, PhD; Kathryn M. McDonald, MM; Douglas K. Owens, MD, MS
Despite advances in supportive care, fulminant-phase inhalational anthrax is usually fatal. Initiation of antibiotic or anthrax antiserum therapy during the prodromal phase is associated with markedly improved survival, although other aspects of care, differences in clinical circumstances, or unreported factors may also have some effect. Earlier diagnosis and faster initiation of appropriate antibiotics are critical to decreasing mortality rates.
Ann Intern Med. 2006;144(4):270-280. doi:10.7326/0003-4819-144-4-200602210-00009
Paul L. Kimmel, MD
This Update includes papers that presented a new way of classifying chronic kidney disease, established a new association between chronic kidney disease and the metabolic syndrome, and compared the equations that are used to define chronic kidney disease. The Update also discusses noteworthy research on the prevention and treatment of diabetic nephropathy, hyperkalemia, and the prevention of contract agent–induced nephropathy.
Ann Intern Med. 2006;144(4):281-285. doi:10.7326/0003-4819-144-4-200602210-00010
Bernhard Glodny, MD; Dorothea E. Glodny, PhD
In 1934, Harry Goldblatt and colleagues published a landmark article: “The Production of Persistent Elevation of Systolic Blood Pressure by Means of Renal Ischemia.” One year earlier, John Loesch had published a similar study in a German-language journal. The central proposition of both papers was the same: Renal ischemia causes persistent hypertension. Although Loesch was the first to produce persistent hypertension by inducing ischemia, his work is essentially unknown. Loesch and Goldblatt deserve equal credit for these important first observations.
Ann Intern Med. 2006;144(4):286-295. doi:10.7326/0003-4819-144-4-200602210-00011
Sidney C. Smith Jr, MD
In this issue, Go and colleagues suggest that the use of statin and β-blocker therapy might favorably alter the initial clinical presentation of coronary heart disease. We need to perform randomized clinical trials to confirm these findings in appropriate patient groups and investigate their mechanisms. If confirmed by such trials, these findings could have a substantial effect on patient care.
Ann Intern Med. 2006;144(4):296-297. doi:10.7326/0003-4819-144-4-200602210-00012
John P.A. Ioannidis, MD; Cynthia D. Mulrow, MD, MSc, Deputy Editor; Steven N. Goodman, MD, PhD
Physicians rely on compendia and product inserts to learn about medication-related harms. These materials offer litanies of possible adverse events, sometimes accompanied by an estimate of how often those events might occur. From whence are the estimates derived? What do they really mean? How can we better measure and understand how many and what kinds of harms may be caused by medications? In this issue, Bent and colleagues remind us that how we define and look for problems markedly affects the numbers of harms that patients report.
Ann Intern Med. 2006;144(4):298-300. doi:10.7326/0003-4819-144-4-200602210-00013
Jon O. Neher, MD
I was driving home late one night when suddenly a dozen red taillights flashed in front of me. I hit my brakes. In my peripheral vision, I caught sight of a pile of clothing lying in the center lane. At first I thought that it was just some garbage that had come off the back of a truck. But as I rolled slowly past, I developed a sickening feeling. The clothing was not arranged randomly. It was held together in some dimly recognizable order.
Ann Intern Med. 2006;144(4):301-302. doi:10.7326/0003-4819-144-4-200602210-00014
Ann Intern Med. 2006;144(4):303. doi:10.7326/0003-4819-144-4-200602210-00015
Ann Intern Med. 2006;144(4):303. doi:10.7326/0003-4819-144-4-200602210-00016
Ann Intern Med. 2006;144(4):303-304. doi:10.7326/0003-4819-144-4-200602210-00017
Ann Intern Med. 2006;144(4):304. doi:10.7326/0003-4819-144-4-200602210-00018
Ann Intern Med. 2006;144(4):304. doi:10.7326/0003-4819-144-4-200602210-00019
Ann Intern Med. 2006;144(4):304-305. doi:10.7326/0003-4819-144-4-200602210-00020
Ann Intern Med. 2006;144(4):305. doi:10.7326/0003-4819-144-4-200602210-00021
Ann Intern Med. 2006;144(4):305-306. doi:10.7326/0003-4819-144-4-200602210-00022
Ann Intern Med. 2006;144(4):306. doi:10.7326/0003-4819-144-4-200602210-00023
Ann Intern Med. 2006;144(4):306-307. doi:10.7326/0003-4819-144-4-200602210-00024
Ann Intern Med. 2006;144(4):307. doi:10.7326/0003-4819-144-4-200602210-00025
Jack Coulehan, MD
Ann Intern Med. 2006;144(4):308. doi:10.7326/0003-4819-144-4-200602210-00026
Ann Intern Med. 2006;144(4):I-22. doi:10.7326/0003-4819-144-4-200602210-00001
Ann Intern Med. 2006;144(4):I-37. doi:10.7326/0003-4819-144-4-200602210-00002
Ann Intern Med. 2006;144(4):I-38. doi:10.7326/0003-4819-144-4-200602210-00003
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use